Home › Lilly angles for arthritis blockbuster
 

Keywords :   


Lilly angles for arthritis blockbuster

2016-03-26 22:04:04| Biotech - Topix.net

And now, the waiting begins. Within six months, Eli Lilly and Co. could know whether the Food and Drug Administration has approved its latest drug, baricitinib, a once-a-day tablet for treating rheumatoid arthritis - a market poised to grow to $80 billion by 2020.

Tags: angles arthritis lilly blockbuster

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Tom Hardy Is Jo Malone Londons New Ambassador for Cypress & Grapevine Cologne Intense
15.05Mooncat Introduces New Hue, Holds Bi-Annual Sale
15.05Eastern North Pacific Tropical Weather Outlook
15.05European Wax Center\'s EWC Treat Brightening Ingrown Hair Wipes Awarded
15.05EchoStar pay TV subscribers down 348,000 in 1Q 2024
15.05Atlantic Tropical Weather Outlook
15.05PBE Makes Investment in Plus-Size Adult Incontinence Products
15.05Flint Group retains EcoVadis Silver Medal for 2024
More »